scholarly article | Q13442814 |
P50 | author | H. Julia Hannay | Q42725599 |
Julia S Benoit | Q56883913 | ||
Lucia Rivera-Lara | Q57756325 | ||
P2093 | author name string | Claudia S Robertson | |
Osama Ahmed | |||
Paul Swank | |||
Alex Valadka | |||
José-Miguel Yamal | |||
Barbara C Tilley | |||
J Clay Goodman | |||
Pratik Doshi | |||
Imoigele P Aisiku | |||
Shankar Gopinath | |||
Santhosh Sadasivan | |||
Hazem Shahin | |||
Hector Saucedo-Crespo | |||
M Laura Rubin | |||
Leslie Neipert | |||
Athena Baldwin | |||
Epo Severe TBI Trial Investigators | |||
Jace M Waguspack | |||
Jovanny Cruz-Navarro | |||
Luciano Ponce | |||
P2860 | cites work | Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress | Q24611053 |
The injury severity score: a method for describing patients with multiple injuries and evaluating emergency care | Q28245876 | ||
THE LASSO METHOD FOR VARIABLE SELECTION IN THE COX MODEL | Q29038535 | ||
A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group | Q29620037 | ||
Optimizing the ongoing search for new treatments for Parkinson disease: using futility designs | Q30810700 | ||
Predicting outcome after traumatic brain injury: development and international validation of prognostic scores based on admission characteristics. | Q33358264 | ||
Dose-dependent neurorestorative effects of delayed treatment of traumatic brain injury with recombinant human erythropoietin in rats | Q35194540 | ||
Design and analysis of phase III trials with ordered outcome scales: the concept of the sliding dichotomy | Q36126534 | ||
Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis | Q36371706 | ||
Effect of erythropoietin on Glasgow Coma Scale and Glasgow Outcome Sale in patient with diffuse axonal injury | Q36470042 | ||
Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury | Q37250532 | ||
Transfusion of red blood cells in patients with a prehospital Glasgow Coma Scale score of 8 or less and no evidence of shock is associated with worse outcomes. | Q37310027 | ||
Enrollment of racially/ethnically diverse participants in traumatic brain injury trials: effect of availability of exception from informed consent | Q37681891 | ||
Transfusions and long-term functional outcomes in traumatic brain injury | Q37683758 | ||
Recombinant human erythropoietin in the treatment of acute ischemic stroke | Q38378327 | ||
Transfusion requirements after cardiac surgery: the TRACS randomized controlled trial | Q38498896 | ||
Report of the American-European consensus conference on ARDS: definitions, mechanisms, relevant outcomes and clinical trial coordination. The Consensus Committee | Q40662879 | ||
Safety and Efficacy of Erythropoietin in Traumatic Brain Injury Patients: A Pilot Randomized Trial | Q42413212 | ||
Delayed administration of erythropoietin reducing hippocampal cell loss, enhancing angiogenesis and neurogenesis, and improving functional outcome following traumatic brain injury in rats: comparison of treatment with single and triple dose | Q42737005 | ||
Erythropoiesis stimulating agent administration improves survival after severe traumatic brain injury: a matched case control study | Q44213738 | ||
The diagnosis of head injury requires a classification based on computed axial tomography | Q44489764 | ||
Transfusion practices for acute traumatic brain injury: a survey of physicians at US trauma centers | Q44802066 | ||
The effect of red blood cell transfusion on cerebral oxygenation and metabolism after severe traumatic brain injury | Q45204432 | ||
Low hematocrit levels increase intracranial pressure in an animal model of cryogenic brain injury | Q46092807 | ||
The effect of blood transfusion on brain oxygenation in children with severe traumatic brain injury | Q46465723 | ||
Prediction of outcome in traumatic brain injury with computed tomographic characteristics: a comparison between the computed tomographic classification and combinations of computed tomographic predictors | Q46838100 | ||
Guidelines for the management of severe traumatic brain injury | Q48163575 | ||
Neuroprotection with erythropoietin administration following controlled cortical impact injury in rats | Q48182845 | ||
Structured interviews for the Glasgow Outcome Scale and the extended Glasgow Outcome Scale: guidelines for their use. | Q48401602 | ||
Effect of a liberal versus restrictive transfusion strategy on mortality in patients with moderate to severe head injury | Q48425902 | ||
Erythropoiesis-stimulating agent administration and survival after severe traumatic brain injury: a prospective study | Q48606982 | ||
Transfusion strategies for patients in pediatric intensive care units. | Q50698283 | ||
Improved survival of critically ill trauma patients treated with recombinant human erythropoietin | Q81770219 | ||
P433 | issue | 1 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | erythropoietin | Q218706 |
traumatic brain injury | Q1995526 | ||
P304 | page(s) | 36-47 | |
P577 | publication date | 2014-07-01 | |
P1433 | published in | The Journal of the American Medical Association | Q1470970 |
P1476 | title | Effect of erythropoietin and transfusion threshold on neurological recovery after traumatic brain injury: a randomized clinical trial | |
P478 | volume | 312 |
Q38681722 | A State-of-the-Science Overview of Randomized Controlled Trials Evaluating Acute Management of Moderate-to-Severe Traumatic Brain Injury. |
Q38684753 | A joint logistic regression and covariate-adjusted continuous-time Markov chain model. |
Q90327613 | A meta-analysis and systematic review evaluating the use of erythropoietin in total hip and knee arthroplasty |
Q35192848 | ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes. |
Q47755572 | Acute Management of Traumatic Brain Injury |
Q38790372 | Acute or Delayed Treatment with Anatabine Improves Spatial Memory and Reduces Pathological Sequelae at Late Time-Points after Repetitive Mild Traumatic Brain Injury |
Q49375977 | Alternative Erythropoietin Receptors in the Nervous System |
Q36269794 | Anemia and Blood Transfusion in Patients with Isolated Traumatic Brain Injury |
Q26745655 | Anemia management after acute brain injury |
Q40721720 | Association Between Relative Anemia and Early Functional Recovery After Severe Traumatic Brain Injury (TBI). |
Q48036890 | Association between delivery methods for red blood cell transfusion and the risk of venous thromboembolism: a longitudinal study |
Q36210438 | Association of transfusion red blood cell storage age and blood oxygenation, long-term neurologic outcome, and mortality in traumatic brain injury |
Q39948879 | Beneficial Effect of Erythropoietin Short Peptide on Acute Traumatic Brain Injury |
Q92727799 | Benefits of red blood cell transfusion in patients with traumatic brain injury |
Q38774608 | Beta-Blockers and Traumatic Brain Injury: A Systematic Review, Meta-analysis, and Eastern Association for the Surgery of Trauma Guideline |
Q39890311 | Blood Transfusion is Associated with Increased Perioperative Morbidity and Adverse Oncologic Outcomes in Bladder Cancer Patients Receiving Neoadjuvant Chemotherapy and Radical Cystectomy |
Q38298655 | Blood transfusion practices in neuroanaesthesia |
Q42722918 | Carbamylated Erythropoietin Outperforms Erythropoietin in the Treatment of AKI-on-CKD and Other AKI Models |
Q36001623 | Causal Structure of Brain Physiology after Brain Injury from Subarachnoid Hemorrhage |
Q40002588 | Cerebral Microcirculation during Experimental Normovolaemic Anemia |
Q36791150 | Charting a course for erythropoietin in traumatic brain injury. |
Q39443587 | Coagulopathy and haemorrhagic progression in traumatic brain injury: advances in mechanisms, diagnosis, and management |
Q49017368 | Determinants of red blood cell transfusion in pediatric trauma patients admitted to the intensive care unit. |
Q90611230 | Discharge Hemoglobin Level and 30-Day Readmission Rates After Coronary Artery Bypass Surgery |
Q100395179 | Drugs with anti-inflammatory effects to improve outcome of traumatic brain injury: a meta-analysis |
Q50076601 | EPO improved neurologic outcome in rat pups late after traumatic brain injury |
Q47641132 | EPO in traumatic brain injury: two strikes…but not out? |
Q92537464 | Editorial: Developing Successful Neuroprotective Treatments for TBI: Translational Approaches, Novel Directions, Opportunities and Challenges |
Q35941906 | Effect of Hemoglobin Transfusion Threshold on Cerebral Hemodynamics and Oxygenation |
Q26749482 | Effect of restrictive versus liberal transfusion strategies on outcomes in patients with cardiovascular disease in a non-cardiac surgery setting: systematic review and meta-analysis |
Q42276992 | Effects of Quercetin and Mannitol on Erythropoietin Levels in Rats Following Acute Severe Traumatic Brain Injury |
Q50277067 | Effects of Red Blood Cell Transfusion on Long-Term Disability of Patients with Traumatic Brain Injury. |
Q57155530 | Electrophysiological Signature Reveals Laminar Structure of the Porcine Hippocampus |
Q41908695 | Embracing Biological and Methodological Variance in a New Approach to Pre-Clinical Stroke Testing |
Q28087789 | Emerging therapies in traumatic brain injury |
Q47911477 | Encouraging single-unit transfusions: a superior patient blood management strategy? |
Q36246631 | Erythropoiesis stimulating agents and reno-protection: a meta-analysis |
Q28066377 | Erythropoietin and mTOR: A "One-Two Punch" for Aging-Related Disorders Accompanied by Enhanced Life Expectancy |
Q48140419 | Erythropoietin in Traumatic Brain Injury: An Answer Will Come Soon |
Q47806649 | Erythropoietin in diabetic retinopathy. |
Q40447654 | Erythropoietin in traumatic brain injury (EPO-TBI): a double-blind randomised controlled trial. |
Q47156500 | Erythropoietin regulates immune/inflammatory reaction and improves neurological function outcomes in traumatic brain injury. |
Q39385930 | Evaluation of RBC Transfusion Practice in Adult ICUs and the Effect of Restrictive Transfusion Protocols on Routine Care |
Q34670021 | Evidence base for restrictive transfusion triggers in high-risk patients |
Q48042344 | Evidence-based medicine: Save blood, save lives |
Q28079256 | Evidence-based review of oral traditional Chinese medicine compound recipe administration for treating weight drop-induced experimental traumatic brain injury |
Q55413545 | Extended Erythropoietin Treatment Prevents Chronic Executive Functional and Microstructural Deficits Following Early Severe Traumatic Brain Injury in Rats. |
Q46451320 | FGF2 Attenuates Neural Cell Death via Suppressing Autophagy after Rat Mild Traumatic Brain Injury. |
Q48251901 | Focus on clinical neuroscience |
Q64111398 | Glasgow Outcome Scale Measures and Impact on Analysis and Results of a Randomized Clinical Trial of Severe Traumatic Brain Injury |
Q38608377 | Harms of off-label erythropoiesis-stimulating agents for critically ill people |
Q41686292 | Hemoglobin Area and Time Index Above 90 g/L are Associated with Improved 6-Month Functional Outcomes in Patients with Severe Traumatic Brain Injury |
Q33808430 | Hemoglobin concentrations and RBC transfusion thresholds in patients with acute brain injury: an international survey |
Q41193822 | Higher haemoglobin levels and dedicated trauma admission are associated with survival after severe traumatic brain injury. |
Q37724782 | Imaging and serum biomarkers reflecting the functional efficacy of extended erythropoietin treatment in rats following infantile traumatic brain injury. |
Q26752496 | Impact of Transfusion on Cancer Growth and Outcome |
Q39356470 | Impact of red blood cell transfusion strategies in haemato-oncological patients: a systematic review and meta-analysis. |
Q38875861 | Implementation of Neurocritical Care Is Associated With Improved Outcomes in Traumatic Brain Injury |
Q26992292 | Indications for blood and blood product transfusion |
Q88720568 | Indications for red cell transfusions in pediatric patients |
Q35611476 | Investigational agents for treatment of traumatic brain injury |
Q42762679 | Is erythropoietin a worthy candidate for traumatic brain injury or are we heading the wrong way? |
Q89581411 | Is haemoglobin below 7.0 g/dL an optimal trigger for allogenic red blood cell transfusion in patients admitted to intensive care units? A meta-analysis and systematic review |
Q64080372 | Longitudinal Changes in Disability Rating Scale Scores: A Secondary Analysis Among Patients With Severe TBI Enrolled in the Epo Clinical Trial |
Q47237235 | MCC950, the selective NLRP3 inflammasome inhibitor protects mice against traumatic brain injury |
Q39345424 | Medical Management of the Severe Traumatic Brain Injury Patient |
Q95820947 | Meta-analysis with Trial Sequential Analysis on the Efficacy and Safety of Erythropoietin in Traumatic Brain Injury: A New Paradigm |
Q89866105 | MicroRNA sequencing of rat hippocampus and human biofluids identifies acute, chronic, focal and diffuse traumatic brain injuries |
Q38388853 | Molecular mechanisms of erythrocyte aging |
Q57170404 | Multi-Center Pre-clinical Consortia to Enhance Translation of Therapies and Biomarkers for Traumatic Brain Injury: Operation Brain Trauma Therapy and Beyond |
Q58566923 | Neuroprotection in Traumatic Brain Injury: Mesenchymal Stromal Cells can Potentially Overcome Some Limitations of Previous Clinical Trials |
Q35503413 | Neuroprotection in acute brain injury: an up-to-date review |
Q92964494 | Neurotherapeutic potential of erythropoietin after ischemic injury of the central nervous system |
Q48142126 | Non-invasive diagnosis and treatment strategies for traumatic brain injury: an update |
Q90301369 | Paths to Successful Translation of New Therapies for Severe Traumatic Brain Injury in the Golden Age of Traumatic Brain Injury Research: A Pittsburgh Vision |
Q28647190 | Patient blood management: it is time to streamline targeted therapy options |
Q55059568 | Patient blood management: where's the bottom? |
Q39008879 | Peptide Pharmacological Approaches to Treating Traumatic Brain Injury: a Case for Arginine-Rich Peptides |
Q36060634 | Pharmacologic Neuroprotection for Functional Outcomes After Traumatic Brain Injury: A Systematic Review of the Clinical Literature |
Q90197287 | Pioglitazone treatment prior to transplantation improves the efficacy of human mesenchymal stem cells after traumatic brain injury in rats |
Q37258111 | Plasma cytokines IL-6, IL-8, and IL-10 are associated with the development of acute respiratory distress syndrome in patients with severe traumatic brain injury |
Q61812558 | Prehospital and Emergency Care in Adult Patients with Acute Traumatic Brain Injury |
Q64113696 | Prognosis of Six-Month Glasgow Outcome Scale in Severe Traumatic Brain Injury Using Hospital Admission Characteristics, Injury Severity Characteristics, and Physiological Monitoring during the First Day Post-Injury |
Q39947681 | Progressive hemorrhagic injury after severe traumatic brain injury: effect of hemoglobin transfusion thresholds |
Q46172024 | Protein Biomarkers and Neuroproteomics Characterization of Microvesicles/Exosomes from Human Cerebrospinal Fluid Following Traumatic Brain Injury. |
Q92145307 | Public Approval of Exception From Informed Consent in Emergency Clinical Trials: A Systematic Review of Community Consultation Surveys |
Q53567876 | Pyruvate Is Superior to Citrate in Oral Rehydration Solution in the Protection of Intestine via Hypoxia-Inducible Factor-1 Activation in Rats With Burn Injury. |
Q36750167 | Recent Advances in Preventing Adverse Reactions to Transfusion |
Q40607264 | Red Cell Transfusion Triggers and Postoperative Outcomes After Major Surgery. |
Q50245118 | Red blood cells stored 35 days or more are associated with adverse outcomes in high-risk patients |
Q54838335 | Red cell transfusion in the critically ill patient. |
Q36247651 | Regeneration in the nervous system with erythropoietin |
Q39627599 | Relative impact of a patient blood management program on utilization of all three major blood components |
Q49795224 | Reproducibility of clinical research in critical care: a scoping review |
Q30238759 | Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem cell support. |
Q38389607 | Restrictive versus liberal transfusion strategy for red blood cell transfusion: systematic review of randomised trials with meta-analysis and trial sequential analysis |
Q39306479 | Severe traumatic brain injury: targeted management in the intensive care unit. |
Q47226017 | Should Transfusion Trigger Thresholds Differ for Critical Care Versus Perioperative Patients? A Meta-Analysis of Randomized Trials |
Q43973725 | Should red blood cell transfusion be individualized? No. |
Q38977560 | Single-unit transfusions and hemoglobin trigger: relative impact on red cell utilization |
Q47679937 | TBI-the most complex disease in the most complex organ: the CENTER-TBI trial-a commentary |
Q42339639 | Targeted therapeutic mild hypercapnia after cardiac arrest. |
Q48219974 | The Effect of Red Blood Cell Transfusion on Cerebral Autoregulation in Patients with Severe Traumatic Brain Injury |
Q64111058 | The European guideline on management of major bleeding and coagulopathy following trauma: fifth edition |
Q27339343 | The European guideline on management of major bleeding and coagulopathy following trauma: fourth edition |
Q39963920 | The Negative Impact of Anemia in Outcome from Traumatic Brain Injury |
Q86274178 | The Rheology of Subarachnoid Hemorrhage |
Q55426553 | The currency, completeness and quality of systematic reviews of acute management of moderate to severe traumatic brain injury: A comprehensive evidence map. |
Q58581801 | The effects of normovolemic anemia and blood transfusion on cerebral microcirculation after severe head injury |
Q30235977 | The far-reaching scope of neuroinflammation after traumatic brain injury |
Q36515525 | The incidence of ARDS and associated mortality in severe TBI using the Berlin definition |
Q57152125 | Therapeutic hypothermia and targeted temperature management for traumatic brain injury: Experimental and clinical experience |
Q36909393 | Therapeutic hypothermia and targeted temperature management in traumatic brain injury: Clinical challenges for successful translation |
Q38687477 | Thrombotic and Infectious Morbidity Are Associated with Transfusion in Posterior Spine Fusion |
Q64319043 | Transfusion Practices Among General Surgeons at a Tertiary Care Center: a Survey Based Study |
Q48733691 | Transfusion in Traumatic Brain Injury |
Q37728294 | Transfusion of red blood cells in patients with traumatic brain injuries admitted to Canadian trauma health centres: a multicentre cohort study |
Q47840505 | Transfusion practices in traumatic brain injury |
Q64101807 | Transfusion requirements after head trauma: a randomized feasibility controlled trial |
Q30243882 | Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. |
Q38315925 | Traumatic brain injury in 2014. Progress, failures and new approaches for TBI research |
Q38678261 | Traumatic brain injury research highlights in 2015. |
Q38538072 | Treatment of traumatic brain injury with anti-inflammatory drugs. |
Q47944945 | Treatment options for severe traumatic brain injuries in children: current therapies, challenges, and future prospects |
Q39061409 | Venous thromboembolic events in critically ill traumatic brain injury patients. |
Q91671313 | WSES consensus conference guidelines: monitoring and management of severe adult traumatic brain injury patients with polytrauma in the first 24 hours |
Q52577003 | [Appropriate use of red blood cell transfusion in the emergency department before and after a specific protocol]. |
Q53656120 | [Intensive care treatment after aneurysmal subarachnoid hemorrhage]. |
Q52686811 | [Intensive care treatment of traumatic brain injury in multiple trauma patients : Decision making for complex pathophysiology]. |
Search more.